secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
CIK:        0001979414
Form:       8-K
Filed at:   2026-05-18T21:00:15+00:00
Accession:  0001829126-26-005421
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeOnc reports Q1 net loss $8.8M; NEO212 Phase 1 complete, NEO100 interim data Aug 2026
--------------------------------------------------------------------------------

- Net loss $8.8M ($0.38/diluted) vs $32.3M ($1.78) in Q1 2025; G&A down to $489K, R&D up to $1.29M.
- Cash $138,601 at Mar 31; $10M PIPE from Cinctive Capital and $10M undrawn credit line fund ops into Sep 2026.
- NEO212 Phase 1 complete, RP2D set at 610 mg; FDA End-of-Phase 1 meeting planned for potential registrational Phase 2.
- NEO100 Phase 2a fully enrolled in IDH1-mutant high-grade glioma; interim data readout expected August 2026.
- Appointed David Choi as CAO; CEO Amir Heshmatpour purchased >$500k of NTHI shares in open market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1979414/000182912626005421/0001829126-26-005421-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1979414/000182912626005421/neonctechnologies_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-26-005421

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer